Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.69 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902324 | 1.00 | LMNA (1.00) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL3532304 | 0.88 | LMNA (0.79) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL3532302 | 0.88 | LMNA (0.79) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL10309039 | 0.85 | PFKFB3 (0.81) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL10275355 | 0.85 | PFKFB3 (0.81) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL5717629 | 0.84 | LMNA (0.73) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL6890723 | 0.84 | LMNA (1.00) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL5717630 | 0.84 | LMNA (0.73) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL6890727 | 0.84 | LMNA (1.00) | LMNAKDM4EMAPTSMN1; SMN2HTT | |
| SCHEMBL30209642 | 0.84 | LMNA (0.73) | LMNAKDM4EMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114340374-B | Sowing device and method for treating seeds during planting | 先正达参股股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | Sunovion Pharamaceuticals Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| EP-2861596-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharamaceuticals Inc. | 2018-09-13 | — | — | US | disclosed |
| US-9994590-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2017-02-09 | — | — | US | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-9505751-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-6417366-B2 | CHEMICAL INTERMEDIATE FOR MACROLACTONE ANTIBIOTIC | ABBOTT LABORATORIES | 2002-07-09 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| EP-1192139-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | Abbott Laboratories (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2002-01-31 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| WO-2001000582-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-01-04 | — | — | WO | disclosed |
| US-5334597-A | Anti-asthmatic, antiallergic, antiinflammatory, cytoprotective treats angina, cerebral spasm, nephritis, hepatitis, uveitis, endotoxemia and allograft rejection | MERCK FROSST CANADA, INC. (CA) | 1994-08-02 | — | — | US | disclosed |
| EP-0538000-A1 | Indole and indazole carbamates as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-04-21 | — | — | EP | disclosed |
| US-5039684-A | Absorption when administered orally | VALEAS S. P. A. (IT) | 1991-08-13 | — | — | US | disclosed |
| EP-0384450-A1 | Tetrazole amide derivatives of heterocyclic alkenyl acids and their use as antiallergic substances | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | LMNA 3931/4885KDM4E 3058/4885MAPT 2546/4885 |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | LMNA 2445/4885KDM4E 969/4885MAPT 778/4885 |
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | LMNA 2445/4885KDM4E 969/4885MAPT 778/4885 |
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | PDE10A, PDE2A, PDE3A | LMNA 4079/4885KDM4E 1418/4885MAPT 1006/4885 |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | LMNA 2600/4885KDM4E 211/4885MAPT 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.